Pomerantz law firm investigates claims
NEW YORK, October 03, 2021 (GLOBE NEWSWIRE) – Pomerantz LLP is investigating claims on behalf of investors of Altimmune, Inc. (“Altimmune” or the “Company”) (NASDAQ: ALT). These investors are advised to contact Robert S. Willoughby at [email protected] or 888-476-6529, ext. 7980.
The purpose of the investigation is to determine whether Altimmune and any of its officers and / or directors have engaged in securities fraud or other illegal business practices.
[Click here for information about joining the class action]
On September 28, 2021, Altimmune released 12-week data from the Australian Phase 1 trial for its product candidate pemvidutide in overweight and obese volunteers. While the company touted the study’s 1.8 mg arm’s effectiveness, its side effects stood out. For example, in the 1.8 mg arm, out of nine participants, approximately 56% had experienced mild nausea, the highest percentage in the multiple-dose ascending (MAD) portion of the study.
Following this news, Altimmune’s share price fell $ 3.88 per share, or 25.54%, over three trading sessions, to close at $ 11.31 per share on September 30, 2021.
Pomerantz LLP, with offices in New York, Chicago, Los Angeles, Paris and Tel Aviv, is recognized as one of the leading firms in the areas of corporate, securities and antitrust litigation. Founded by the late Abraham L. Pomerantz, known as the Dean of the Class Actions Bar, Pomerantz was a pioneer in the field of securities class actions. Today, more than 85 years later, Pomerantz continues the tradition he established, fighting for the rights of victims of securities fraud, breach of fiduciary duty and professional misconduct. The firm has recovered numerous multi-million dollar damages on behalf of the members of the group. See www.pomlaw.com.
Robert S. Willoughby
888-476-6529 ext 7980